伊立替康、卡培他滨联合放疗对直肠癌的新辅助治疗

Neoadjuvant therapy of irinotecan and capecitabine combined with radiotherapy for rectal cancer

目的研究伊立替康及卡培他滨联合放疗在直肠癌新辅助治疗的疗效和不良反应情况。方法选择本院2017年10月-2018年10月局部中晚期中、低位直肠癌患者45例,其中治疗组22例,采用伊立替康联合卡培他滨新辅助化疗;观察组23例,采用卡培他滨单药新辅助化疗。2组均给予术前放疗。观察术后pCR率和放化疗期间不良反应情况。结果治疗组放化疗后pCR率为36.4%,对照组pCR为8.7%,差异具有统计学意义;与对照组比较治疗组的不良反应无统计学差异。结论术前伊立替康、卡培他滨联合放疗可提高局部进展期直肠癌的pCR率,不良反应。

Objective To explore the efficacy and adverse reactions of irinotecan and capecitabine combined with radiotherapy in neoadjuvant treatment of rectal cancer.Methods From October 2017 to October 2018,45 patients with locally advanced middle and low rectal cancer were selected in our hospital,including 22 patients in the treatment group who received irinotecan combined with capecitabine neoadjuvant chemotherapy.23 cases in the observation group were treated with capecitabine single drug neoadjuvant chemotherapy.Both groups were given preoperative radiotherapy.The rate of PVR and adverse reactions during radiotherapy and chemotherapy were observed.Results The pCR rate of the treatment group was 36.4%after chemoradiotherapy and 8.7%in the control group.There was statistical difference between the two groups.There was no significant difference in adverse reactions between the treatment group and the control group.Conclusions Preoperative irinotecan and capecitabine combined with radiotherapy can improve the pCR rate of locally advanced rectal cancer,and the adverse reactions are normal.